Boosting Brain Protein SORLA Reduces Toxic Tau Tangles and Protects Synapses in Mice

Researchers at Sanford Burnham Prebys report this week, in a study published Tuesday in Science Advances, that raising levels of a brain protein called SORLA reduced toxic tau tangles, brain shrinkage, and synapse damage in mice engineered to develop Alzheimer’s-like disease.

The work matters because tau tangles, along with amyloid-beta plaques, are the two pathological hallmarks of Alzheimer’s disease — and most current treatments target amyloid, leaving tau largely unaddressed. ScienceDaily reported the findings in detail; themorning.science corroborated the core result, describing SORLA boosting as a potential “natural defence” against Alzheimer’s while stressing it is early-stage work, not a proven therapy.

“When you upregulate SORLA, you can suppress the negative effects found in tauopathies,” said Huijie Huang, PhD, who works as a staff scientist in the Huang laboratory at Sanford Burnham Prebys and served as the study’s lead author. “We found there was less brain atrophy and less tau accumulation, which was very exciting to see.”

When the researchers bred mice to produce extra human SORLA, tau damage eased. When they deleted the gene that makes SORLA — called Sorl1 — the damage worsened, ScienceDaily reported. Both directions of the experiment point the same way: this protein appears to actively protect the brain.

SORLA protein protects mice from tau tangles

  • Scientists found that a brain protein called SORLA protects mice against the tau tangles that drive Alzheimer’s — and that removing it makes the damage worse.
  • This is mouse research, published in Science Advances this week; there is no SORLA-based treatment available for patients today.
  • The team also identified a signaling pathway, the plexin-B family of receptors, for which drugs already exist — a possible shortcut toward future therapies.

What tau does to the brain — and where SORLA fits in

Tau is not a villain under normal conditions. It stabilizes microtubules, the tiny internal scaffolding that keeps neurons healthy and connected. In Alzheimer’s and related disorders, collectively called tauopathies, tau becomes abnormal, undergoes a process called hyperphosphorylation — too many phosphate groups attach to the protein and change its behavior — and clumps into tangles that disrupt nerve-cell function and contribute to cognitive decline.

Story on The Morning Science
Photo: themorning.science

SORLA, short for sorting-related receptor with A-type repeats, was already known to limit production of amyloid-beta, the other major Alzheimer’s protein. What was unknown was its effect on tau.

“In the last 15 or 20 years, considerable data has come out from our lab and other groups showing that SORLA can suppress one of the hallmarks of Alzheimer’s disease — amyloid-beta generation and accumulation,” said Timothy Huang, PhD, assistant professor in the Center for Neurologic Diseases at Sanford Burnham Prebys, in remarks carried by ScienceDaily.

“Very little was known, however, about whether SORLA affected the tau tangles reflected on the other side of the coin in Alzheimer’s disease.”

One deletion made everything worse

The contrast the researchers documented is stark. In mice with extra SORLA, the protein reduced hyperphosphorylation, limited misfolded tau from acting as “seeds” that spread aggregation, preserved synapses — the connections through which neurons communicate — and protected synaptic plasticity, the brain’s ability to remodel those connections for learning and memory.

Deleting Sorl1 produced the opposite outcome. “The opposite turned out to be true when we deleted the ability to produce SORLA proteins,” said Tim Huang, senior and corresponding author of the manuscript. “A lack of SORLA exacerbated the harmful effects observed in tauopathies.”

Some people carry Sorl1 mutations that may disrupt production or activity of the protein, which gives the mouse deletion experiment a human-relevant background, at least in principle.

A druggable pathway surfaced in the data

To understand why SORLA levels mattered so much, the team combined single-cell sequencing — measuring gene activity in individual brain cells — with spatial mapping of RNA and proteins in tissue. Higher SORLA prevented harmful changes in protein production at synapses and calmed abnormal gene activity in glial cells, the supporting cells whose overactivation contributes to neurodegeneration.

One signal stood out. “One particularly notable finding that we can build on is the upregulation of a member of the plexin-B family of receptors in the absence of SORLA,” Huijie Huang said, as quoted by ScienceDaily.

“There are unique drugs that can target this class of receptors that we may be able to apply to tau-related dementia disorders,” Tim Huang told ScienceDaily. “One potential future direction is to repurpose these drugs to target overactivation of glial cells and perhaps reverse some of the phenotypes in tauopathies.”

Who funded the work, and what it cannot yet tell us

The research received funding from the National Institutes of Health, the National Cancer Institute and the National Institute on Aging — government, non-commercial backers whose role deserves clear acknowledgment, since preliminary results of this kind are frequently accompanied by inflated claims from companies seeking profit.

Every protective effect reported this week was demonstrated in mice. The researchers themselves flagged the limitation: mouse cells and human cells behave differently. Their planned next step is to transplant human neurons or glial cells into mouse brains to watch how SORLA mutations behave in a human cell inside a diseased brain environment.

Finding Extra SORLA (mice) SORLA deleted (mice)
Tau accumulation Reduced Exacerbated
Brain atrophy Less Worse
Synapses and plasticity Protected Not protected
Glial cell gene activity Normalized Abnormal

No SORLA therapy exists; consult a doctor

  • There is no SORLA therapy, supplement, or intervention available to patients; any product marketed as boosting this protein should be treated with skepticism.
  • People concerned about memory or cognitive decline should consult a physician or neurologist, not wait for therapies derived from preclinical mouse research.
  • Do not interpret this finding as grounds to change any current treatment regimen; established care decisions belong with a clinician who knows the patient’s history.

Where this research goes from here

The team’s roadmap is specific: characterize how individual brain-cell types respond to rising or falling SORLA levels, then use human-cell transplantation into mouse brains to study SORLA dysfunction in a human context.

“Mouse cells and human cells are different,” Tim Huang said in the ScienceDaily report. “Because we’re looking at human disease, it’s more informative if we can observe the modulation and dysfunction of SORLA in the context of a human cell inside of a diseased brain environment.”

References

  • Science Advances — original study by the Sanford Burnham Prebys team (Huijie Huang, Timothy Huang, and colleagues), November 2026
  • ScienceDaily — detailed coverage of the Sanford Burnham Prebys findings, published this week
  • themorning.science — corroborating report on the SORLA tau findings, November 18, 2026

This article is journalistic coverage of preclinical research and is not medical advice. Findings in mice do not establish efficacy or safety in humans.

Photo of author

Health Desk

Health Desk at Archyde.

Skydance CEO David Ellison Praises Elon Musk, Open to Future Collaboration

Senate GOP Advances FCC Nominee 15-0 After Democrats Boycott Vote